Navigation Links
Cephalon Shareholders Approve Acquisition by Teva
Date:7/14/2011

FRAZER, Pa., July 14, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its stockholders voted to approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion.

The transaction remains under review by the U.S. Federal Trade Commission and the European Commission.  Cephalon and Teva continue to operate as two independent companies pending those clearances.  

About Cephalon

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 170 products in nearly 100 countries. More information on Cephalon and its products is available at http://www.cephalon.com/.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide the Cephalon current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing de
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... to anti-clotting drug, CHICAGO, March 29 ... dose of a medication that prevents blood clotting,significantly ... coronary interventions (PCI), according to a multicenter study,reported ... the SCAI,Annual Scientific Sessions in Partnership with ACC ...
... ,culotte, technique better?, CHICAGO, March 29 When ... of two coronary arteries -- or a,bifurcation lesion -- ... vessels without blocking the opening to the side branch. ... on which of,two techniques produces the best long-term results ...
Cached Medicine Technology:Tailored Clopidogrel Dosing Improves PCI Outcomes 2Tailored Clopidogrel Dosing Improves PCI Outcomes 3Stenting Techniques Vie in Branchpoint Lesions 2
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival ... cancer of the abdomen when treated with cytoreductive ... to a first-of-its-size analysis by physicians at Wake ... has the largest reported, single-center experience with cytoreductive ... Levine, M.D., and analysis of 20 years, worth ...
(Date:4/17/2014)... cent of Canadians surveyed said they would participate in ... number of genetic conditions, only 80 per cent said ... would sequence their newborns, genomes.,Most newborns in North America ... or two of life in which a tiny amount ... for about five to 54 conditions, depending on the ...
(Date:4/17/2014)... more research to be carried out into HIV ... In a paper in The Lancet Infectious ... colleagues in the department of Parasitology and researchers ... University of Cambridge and the Royal Veterinary College ... of HIV/AIDS and schistosomiasis of children, and found ...
(Date:4/16/2014)... SAN ANTONIO, Texas (April 16, 2014) A team that ... of Texas Health Science Center at San Antonio, Johns Hopkins ... protein that helps a common fungus to infect the body. ... infections, diaper rashes and oral thrush, and is the most ...
(Date:4/15/2014)... Handling frozen fish caused nearly half of all injuries ... injuries on freezer-longliner vessels operating off the coast of ... Many of those injuries and others aboard the two ... interventions, and the research methods used in the study ...
Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Changes in processing, handling could reduce commercial fishing injuries 2
... PARSIPPANY, N.J., July 14 alli spokeswoman Wynonna Judd ... of Fame in Nashville to celebrate her progress since starting the ... having more energy and feeling better. The concert was held exclusively ... commitment to live healthier lives. , , ...
... , , , , ... smoked her first cigarette. Now that she is 45, she still smokes despite ... start smoking if they have a parent who smokes - and in Crawford,s ... met and married her husband - also a smoker - in Roanoke. The ...
... , RESTON, Va., July ... products, announced today that Johns Hopkins Medical Institutions has ... software solution. Perceptrak will assist corporate security personnel in ... campus. , , "Perceptrak ...
... , , ... Nutritionals, Inc. ("Atkins(TM)"), with its market-leading, weight-management shakes and snack bars, has ... Penne Pasta that has half the carbs of regular pasta. Both products ... to reduce the refined carbohydrates and sugars in their diets. Starting ...
... , SAN DIEGO, July 14 ... inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 ... but also its newly approved competitor, Effient. In obtaining a ... to determine the response of an individual patient to their ...
... July 14 (HealthDay News) -- Jogging can be great for ... running can be tough on the body. All that pounding ... ankle sprains, plantar fasciitis (heel pain), knee problems and issues ... sure you take precautions, including wearing the right shoes, taking ...
Cached Medicine News:Health News:Wynonna Judd Celebrates Her Progress on alli With Private Concert at Legendary Venue 2Health News:Wynonna Judd Celebrates Her Progress on alli With Private Concert at Legendary Venue 3Health News:New Survey Highlights Emotional, Financial Toll Multi-Generational Tobacco Use Takes on Parents Sandwiched In Between 2Health News:New Survey Highlights Emotional, Financial Toll Multi-Generational Tobacco Use Takes on Parents Sandwiched In Between 3Health News:New Survey Highlights Emotional, Financial Toll Multi-Generational Tobacco Use Takes on Parents Sandwiched In Between 4Health News:Johns Hopkins Medical Institutions Deploys Perceptrak(R) by Cernium 2Health News:Bread, Pancakes and Pasta on Atkins? Yes, That's Right! 2Health News:Bread, Pancakes and Pasta on Atkins? Yes, That's Right! 3Health News:Accumetrics' VerifyNow(R) P2Y12 Test Provides Physicians With Information to Assess a Patient's Response to Newly-Approved Prasugrel (Effient(R)) 2Health News:Get the Most Out of Your Run 2Health News:Get the Most Out of Your Run 3
Inquire...
Inquire...
CO2 gas object holder and knife freezer for the 8000 Series Sliding Microtome...
Steel Knife with box for the Series 8000 Sliding Microtome. C-Profile, 240 x 33 x13m, 22 Degree angle, tapped to accept holder for Shandon knife sharpener....
Medicine Products: